The data strongly de-risks the myositis registrational program and adds a second pivotal indication in SSc, expanding the addressable market. The PC-free lupus data, while early, supports a potential market expansion thesis. Key catalysts to watch: SSc registrational study initiation in 4Q26, topline DM/ASyS registrational data in mid-2027, and PC-free dose-ranging data across indications. The favorable safety profile supporting outpatient administration could improve commercial adoption if approved.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 3 $3.58entry
- T+1 · 6mo ago −1.96%α −2.35% · $3.51
- T+5 · 5mo ago −15.08%α −11.26% · $3.04
- T+20 · 5mo ago −10.89%α −9.89% · $3.19
- T+60 · 3mo ago −5.59%α −8.09% · $3.38
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Cabaletta Bio presented updated Phase 1/2 clinical data for rese-cel across multiple autoimmune indications at EULAR 2026, including 83% (5/6) of dermatomyositis patients meeting the registrational primary endpoint, encouraging early PC-free lupus data showing deep B cell depletion in 1 of 2 patients, and plans to initiate a systemic sclerosis registrational study in 4Q26. The company also announced a 2H27 BLA submission target for myositis including adult and pediatric data, with potential for a priority review voucher.
Key Facts
- 83% (5/6) of Phase 1/2 dermatomyositis patients achieved IM-free moderate-to-major TIS response at 16 weeks, meeting the registrational primary endpoint threshold
- All 5 DM responders maintained IM-free response through latest follow-up as long as 1.5 years
- First JDM patient achieved IM-free moderate TIS response at 16 weeks, maintained at 32 weeks; JDM to be included in 2H27 BLA submission
- Systemic sclerosis announced as second pivotal indication; single-arm registrational study of ~25 patients with ILD expected to start in 4Q26
- Lowest dose of PC-free rese-cel achieved deep B cell depletion in 1 of 2 lupus patients; second patient had ~90% B cell reduction
- 94% of first 63 patients with preconditioning had no CRS or Grade 1 CRS only; 97% had no ICANS
- BLA submission for adult DM and JDM planned for 2H27, potentially qualifying for a priority review voucher
- SSc patients with ILD showed median 7.5% improvement in FVC at 36 weeks off immunomodulators
Financial Impact
No financial data provided in filing; company is pre-revenue clinical-stage biotech with $572M market cap
Risk Factors
- Phase 1/2 data may not predict registrational trial outcomes; ASyS durability was variable
- PC-free data is very early (2 lupus patients); higher dose cohorts still enrolling
- BLA submission in 2H27 is over a year away; regulatory pathway and approval are uncertain
- Company is pre-revenue with no approved products; will require additional capital to fund registrational trials and commercialization
- Competition from other CD19-CAR T programs in autoimmunity and approved therapies (IVIg, brepocitinib, Vyvgart)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001759138-26-000030 |
| Document: caba-20260603.htm | 0001759138-26-000030 |
| Document: caba-ex99_1.htm | 0001759138-26-000030 |
| Document: 0001759138-26-000030-index-headers.html | 0001759138-26-000030 |
| Document: 0001759138-26-000030-index.html | 0001759138-26-000030 |
| Document: 0001759138-26-000030.txt | 0001759138-26-000030 |
Track record
29 reports on CABA
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +31.59% at T+60 after the May 4, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $1.15 Now $1.11 −3.09% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.32 Now $1.11 −15.91% settles Nov 23
- Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $1.33 Now $1.11 −16.54% settles Nov 19
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $1.45 Now $1.11 −23.45% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
- Nov 8, 20268d ago Press Release Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $1.28 to $1.33 Now $1.11 −13.28% ▲ +3.91% +0.62% vs SPY
- Nov 5, 202611d ago Press Release Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers